1D5A Stock Overview
PLx Pharma Winddown Corp. operates as a commercial-stage drug delivery platform technology company in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
PLx Pharma Winddown Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0005 |
| 52 Week High | US$0.97 |
| 52 Week Low | US$0.0005 |
| Beta | 3.41 |
| 11 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -99.94% |
| 33 Year Change | -99.98% |
| 5 Year Change | -99.98% |
| Change since IPO | -99.99% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1D5A | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -1.2% | -0.02% |
| 1Y | -99.9% | -20.1% | 8.2% |
Return vs Industry: 1D5A underperformed the German Pharmaceuticals industry which returned -28.2% over the past year.
Return vs Market: 1D5A underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| 1D5A volatility | |
|---|---|
| 1D5A Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 1D5A has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 1D5A's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 18 | Pat Lonergan | plxpharma.com |
PLx Pharma Winddown Corp. operates as a commercial-stage drug delivery platform technology company in the United States. The company’s lead product candidates are Vazalore 325 mg for the patients with vascular events, such as heart attacks and clot-related strokes, as well as for use in conditions associated with pain and inflammation, including other aspirin and non-steroidal anti-inflammatory drug products; and Vazalore 81 mg liquid-filled aspirin capsules. Its product pipeline also includes PL1200 Ibuprofen 200 mg; and PL1100 Ibuprofen 400 mg, which are in Phase I clinical stage for pain, inflammation, and fever.
PLx Pharma Winddown Corp. Fundamentals Summary
| 1D5A fundamental statistics | |
|---|---|
| Market cap | €5.36k |
| Earnings (TTM) | -€25.36m |
| Revenue (TTM) | €4.18m |
0.0x
P/S Ratio0.0x
P/E RatioIs 1D5A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1D5A income statement (TTM) | |
|---|---|
| Revenue | US$4.54m |
| Cost of Revenue | US$4.34m |
| Gross Profit | US$203.00k |
| Other Expenses | US$27.78m |
| Earnings | -US$27.58m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.95 |
| Gross Margin | 4.47% |
| Net Profit Margin | -606.91% |
| Debt/Equity Ratio | 0% |
How did 1D5A perform over the long term?
See historical performance and comparison